{"id":935454,"date":"2026-02-10T07:12:31","date_gmt":"2026-02-10T12:12:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/"},"modified":"2026-02-10T07:12:31","modified_gmt":"2026-02-10T12:12:31","slug":"enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/","title":{"rendered":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting"},"content":{"rendered":"

<\/p>\n

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting<\/b><\/p>\n

WATERTOWN, Mass.–(BUSINESS WIRE<\/a>)–Enanta Pharmaceuticals, Inc.<\/a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company\u2019s KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 \u2013 March 2, 2026 in Philadelphia, PA.<\/p>\n

\nDetails of the presentations are as follows:<\/p>\n

Abstract Title: <\/b>Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases
\n
Date: <\/b>Friday, February 27, 2026
\n
Time: <\/b>2:45 \u2013 3:45 PM EST
\n
Poster Number: <\/b>104
\n
Session: <\/b>Allergic Skin Diseases
\n
Location: <\/b>Convention Center, Level 2, Hall E
\n
Presenter: <\/b>Tessa Cressey, Ph.D.<\/p>\n

Abstract Title: <\/b>EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharmacokinetic Profile with Once-Daily Dosing Potential in Humans
\n
Date: <\/b>Friday, February 27, 2026
\n
Time: <\/b>2:45 \u2013 3:45 PM EST
\n
Poster Number: <\/b>038
\n
Session: <\/b>Allergic Skin Diseases
\n
Location: <\/b>Convention Center, Level 2, Hall E
\n
Presenter: <\/b>Yang Li, Ph.D.<\/p>\n

\nAbstracts are available in an online supplement to The Journal of Allergy and Clinical Immunology (JACI)<\/i> platform here<\/a>. Further information about AAAAI 2026 can be found here<\/a>. Posters will be available on Enanta\u2019s website here<\/a> after presentations are held on February 27, 2026.<\/p>\n

About Enanta Pharmaceuticals, Inc.<\/b><\/p>\n

\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta\u2019s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.<\/p>\n

\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae<\/sup> (U.S.) and MAVIRET\u00ae<\/sup> (ex-U.S.) (glecaprevir\/pibrentasvir). A portion of Enanta\u2019s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta\u2019s operations. Please visit www.enanta.com<\/a> for more information.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260210569136\/en\/<\/a><\/span><\/p>\n

Media and Investors Contact:
\n<\/b>
Jennifer Viera
\n
617-744-3848
\n
jviera@enanta.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Pennsylvania Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Genetics Other Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company\u2019s KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 \u2013 March 2, 2026 in Philadelphia, PA. Details of the presentations are as follows: Abstract Title: Discovery of a Potent and Selective KIT inhibitor … <\/p>\n

Continue reading “Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935454","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company\u2019s KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 \u2013 March 2, 2026 in Philadelphia, PA. Details of the presentations are as follows: Abstract Title: Discovery of a Potent and Selective KIT inhibitor … Continue reading "Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T12:12:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting\",\"datePublished\":\"2026-02-10T12:12:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/\"},\"wordCount\":447,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/\",\"name\":\"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-02-10T12:12:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Market Newsdesk","og_description":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company\u2019s KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 \u2013 March 2, 2026 in Philadelphia, PA. Details of the presentations are as follows: Abstract Title: Discovery of a Potent and Selective KIT inhibitor … Continue reading \"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-10T12:12:31+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting","datePublished":"2026-02-10T12:12:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/"},"wordCount":447,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/","name":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-02-10T12:12:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260210569136r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-preclinical-data-for-edp-978-its-kit-inhibitor-in-development-for-the-treatment-of-type-2-immune-diseases-at-the-2026-aaaai-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935454"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935454\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}